Produktname:1-Boc-4-(4-Aminophenyl)piperidine
IUPAC Name:tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate
- CAS：170011-57-1
- Molekulare Formel：C16H24N2O2
- Reinheit：95%+
- Katalognummer：CM180999
- Molekulargewicht：276.38
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:170011-57-1
- Molekulare Formel:C16H24N2O2
- Schmelzpunkt:-
- SMILES-Code:C(=O)(OC(C)(C)C)N1CCC(CC1)C2=CC=C(C=C2)N
- Dichte:
- Katalognummer:CM180999
- Molekulargewicht:276.38
- Siedepunkt:
- Mdl-Nr.:MFCD05861405
- Lagerung:Keep in dark place, store at 2-8°C.
Category Infos
- Piperidines
- Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
- Piperidine,Piperidine Price
- if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- NX-2127
- Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.
- NX-5948
- Nurix announced the presentation of the first findings of clinical responses in the brain for NX-5948. NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
Suche 
+86 21 5895 0110 
